COVID-19: BDR Pharma to launch 400 mg Favipiravir tablets ‘BDFAVI’ in India

By: |
September 4, 2020 5:38 PM

The 'BDFAVI' 400 mg tablets will be priced at Rs 990 for a strip of 10 tablets, BDR Pharma said in a statement. Each tablet will cost Rs 99.

In August, the company launched 200 mg Favipiravir tablets.In August, the company launched 200 mg Favipiravir tablets. (Representative image)

Drug firm BDR Pharmaceuticals on Friday said it plans to launch 400 mg Favipiravir tablets, used for treating COVID-19 patients, in the country.

The ‘BDFAVI’ 400 mg tablets will be priced at Rs 990 for a strip of 10 tablets, BDR Pharma said in a statement. Each tablet will cost Rs 99.

In August, the company launched 200 mg Favipiravir tablets.

“We aim to make BDFAVI available in sufficient quantities to meet the high demand for the drug in the Indian market to help curb the current crisis… introducing a higher dosage is an attempt to ensure a smoother experience to patients and caregivers,” BDR Pharma CMD Dharmesh Shah said.

The company had received approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat patients with mild to moderate COVID-19 symptoms under the brand name BDFAVI, according to the statement.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Total 7.86 lakh healthcare workers got COVID-19 vaccine jabs till Wednesday 6 pm: Centre
2China records dozens new coronavirus cases, defends response
3Bird flue: Over 1,200 bird deaths reported in Delhi since January 6, say officials